Pancreatic β-cell dysfunction and death are determinant events in type 1 diabetes (T1D), but the molecular mechanisms behind β-cell fate remain poorly understood. Alternative splicing is a post-translational mechanism by which a single gene generates different mRNA and protein isoforms, expanding the transcriptome complexity and enhancing protein diversity. Neuron-specific and certain serine/arginine-rich RNA binding proteins (RBP) are enriched in β-cells, playing crucial roles in the regulation of insulin secretion and β-cell survival. Moreover, alternative exon networks, regulated by inflammation or diabetes susceptibility genes, control key pathways and processes for the correct function and survival of β-cells. The challenge ahead of us is to understand the precise role of alternative splicing regulators and splice variants on β-cell function, dysfunction and death and develop tools to modulate it.
intra and extracellular cues. 3 Functionally related transcripts are often coordinately spliced in splicing regulatory networks controlled by master splicing regulators. These networks control complex biologic outcomes such as cell differentiation, lineage determination, tissue identity and organ development. 5 Not all alternative splicing events lead to functional proteins. For instance, an alternative splicing event can result in a non-coding transcript through its functional coupling to the nonsense-mediated decay (NMD) system that affects mRNA stability; alternative splicing can also impact mRNA localization and the regulation of downstream mRNAs by sequestering their splicing regulators or by splicing transcription factors and/or splicing regulators. 6 Technological advances during the last decade, particularly RNA sequencing at high depth, increased our understanding on the role of RNA splicing in biology and disease. 7 The biologic importance of this tightly regulated mechanism is underlined by the fact that mutations or variations in splicing pre-mRNA sequences or in splicing regulatory proteins are associated with several human pathologies. 8 Transcriptome analysis suggests that splicing alterations might contribute to pancreatic β-cell demise in the context of type 1 diabetes (T1D) and type 2 diabetes (T2D). 9, 10 It is becoming increasingly evident that alternative splicing is a crucial regulatory point for β-cell identity, development, function and survival. [11] [12] [13] [14] [15] This review will discuss alternative splicing regulation in pancreatic β-cells in the context of physiology and diabetes, with focus on recent advances in the field not covered by a previous review by our group. 15 
"
Transcriptome analysis suggests that splicing alterations might contribute to pancreatic β-cell demise in the context of T1D and T2D.
" 2 | SPLICING REGULATION-A KEY BIOLOGICAL PHENOMENON
The discontinuous architecture of eukaryotic genes provides evolutionary advantages but requires a well-coordinated splicing regulatory machinery. The splicing events are catalysed by the spliceosome, a dynamic and flexible macromolecular complex. 16 The spliceosome machinery consists of 5 small nuclear ribonucleic acid (snRNA) molecules, called U1, U2, U4, U5 and U6, a common set of Sm proteins, and over a hundred particle-specific proteins, that together constitute the small nuclear ribonucleoproteins (snRNPs). 17 These constitutively expressed snRNPs are the central players in the mRNA splicing and dictate where splicing will occur. 17 Structurally, alternative splicing events can be categorized into 7 main subgroups: (1) skipping/inclusion of a cassette exon; (2) recognition of alternative 3 0 splice site Figure 1B ). These core splice signals, however, are short and degenerated sequences and do not provide the complete information required for the efficient splicing of alternative exons. 18 Other cis-regulatory regions, namely exonic and intronic splicing enhancers (ESEs and ISEs) or silencers (ESSs and ISSs), must be recognized in order to promote positive or negative effects on splicing site recognition ( Figure 1B ).
FIGURE 1
Alternative splicing regulation and alternative splicing events. A, The 7 major categories of alternative splicing events; B, Schematic representation of exon-intron boundaries and snRNP spliceosomal components bound to splicing signals and consensus sequences in the premRNA molecule Some of these regulatory sequences can modulate splicing of exons at distant locations. 19 The information included in these cis-elements, together with their interacting RNA binding proteins (RBP;
trans-acting factors), defines the "road map" for splicing regulation, the so-called "splicing code," that will recruit (or prevent) the association and binding of the splicing machinery to the adjacent splice site(s). 20 These RBPs can be grouped into 2 classes. One class consists of relatively broadly expressed proteins with widespread roles in mRNA biogenesis-the Serine Arginine (SR) rich proteins which, usually promote exon inclusion, and the heterogeneous nuclear ribonucleoproteins (hnRNPs), which have mostly an inhibitory effect, when bound to exons. 21 The ESE and ISE are usually recognized by SR proteins whereas ESS and ISS are often bound by splicing repressors, for example, hnRNP proteins 22 ( Figure 1B exons. The relative usage of an exon is usually described by its inclusion level, and it is measured using the "percent spliced in" (PSI or Ψ )
statistics. 30 The PSI indicates the ratio between the relative abundance of isoforms containing a certain exon over the relative abundance of all isoforms of the gene containing or not that exon. 30 In other words, the PSI value indicates how often an exon appears in all the isoforms of the gene. Methodologically, the analysis of alternative splicing falls into 2 categories: isoform-centric and exon-centric approach. The isoform-centric approach starts by an estimation of the relative amounts of each isoform by quantification tools such as Cufflinks, 31 Flux Capacitor, 32 or RSEM 33 (Table 1) , generating a probabilistic model of the frequency of each isoform in the original sample.
The exon-centric tools, such as MISO, 46 VAST-TOOLS 49 and rMATS 48 quantify usage of annotated exons by calculating read densities for every exon-exon junction and computing the PSI index 30 ( Table 1 ).
The output from these approaches is therefore different. The isoformcentric methods attempt to capture splicing complexity by predicting and reconstructing the full-length transcripts. Since most reads cannot be unequivocally mapped to individual transcripts, further analysis is needed to identify the events.
59
The exon-centric type of analysis provides information about the inclusion levels for every splicing event,
allowing to identify differently spliced exons. This information can be easily used to identify sequence features in modified exons and to design oligonucleotides for further validation experiment. 59 In our previous studies of alternative splicing 9,10,12 we used mostly isoformcentric approaches, particularly Cufflinks and Flux Capacitor, since they are suitable for assembly and abundance quantification of isoforms from mapped reads. On the other hand, in our most recent work we used an exon-centric approach-rMATS-since it provides a more detailed description of the splicing events, a central goal of this particular study. 13 Once the alternative splicing events have been identified, a critical issue is to interpret the profiling data, and to identify splice variants that are potentially associated with particular biological processes. For this purpose, enrichment of gene ontology and pathway terms in differentially spliced genes is a useful approach to identify affected processes. 60 The challenges are to understand how specific events affect protein properties or functions and impacts on particular biological processes. Moreover, understanding how coregulated exon networks are controlled by specific regulatory proteins to promote cell-and tissue-specific functions is a fundamental goal in the field. Structural modifications of particular protein domains and NMD-mediated transcript degradation are the main functional outcomes of splicing. 61 Several computational algorithms have been developed to address these questions 56, 57 (Table 1 ). The recently developed ASpedia database integrates several layers of information covering genomic features as well as isoform-level functions. 58 Integration of transcriptomic and proteomic data (proteogenomics) is an emerging field that can help to identify expressed splice variants at protein level. 62 It is important to keep in mind, however, that RNA sequencing is presently much more sensitive than mass-spectrometry proteomics. For instance, in our own parallel RNA-seq and proteomic analysis of human islets or EndoC-β1 cells exposed to different cytokines (using state-of-the art technology) we usually detect around 50.000 of the expected 80.000-100.000 splice variants, and around 10.000-12.000 of the expected >200.000 proteins (unpublished data). RNA-seq can be integrated with other high-throughput assay to build RNA splicing maps that allow to visualize, in a genome-wide scale, how the binding of a RBP in a given position affects the splicing of a particular exon. 63 The most widely used method to unveil protein-RNA interactions is the UV crosslinking immunoprecipitation (CLIP) coupled with high-throughput RNA sequencing. 64 Novel improvements of this method now allows to reach nucleotide resolution, by using the individual-nucleotide resolution UV crosslinking and immunoprecipitation approach (iCLIP). 65 Computational approaches combining genomic variations with transcriptomic data enables the identification of splicing quantitative trait locus (sQTL), providing information about the association between splicing alterations and SNPs. 66 
| THE "NEURON-SPECIFIC" SPLICING FACTORS THAT REGULATE β-CELL FUNCTION
Alternative splicing plays a central role in neuronal development and physiology. 67 Mutations affecting several RNA binding proteins lead to neuronal dysfunction and disease. 68 Despite different embryological origins, neuronal cells and pancreatic β-cells share many similarities, ranging from analogous signal transduction to development steps and gene expression. 69 This is due, at least in part, to the absence of the inhibitory transcription factor REST (repressor element 1 silencing transcription factor) in both β-cells and neurons. 70 β-cells express several neural-enriched splicing factors, and the global analysis of splicing regulators expressed in β-cells show that they cluster together with brain as compared to other tissues. 14 Among the already studied splicing factors expressed preferentially in brain and β-cells, we found that NOVA 1 and 2, RBFOX1, RBFOX2 and ELAVL4 affect β-cell function and survival. 12, 14 The "neuron-specific" NOVA proteins were first identified as neuronal antigens in an autoimmune neurologic disease characterized by failure of motor systems inhibition. 71 In the central nervous system (CNS), NOVA 1 and 2 have indistinguishable biochemical properties but mutually exclusive expression. 71 NOVA1 is highly expressed in human β-cells-to the same extend as in neurons and > 10-fold higher than in liver, spleen, colon or lung. 10 It regulates β-cell function and survival through splicing modifications of genes involved in exocytosis, apoptosis, insulin receptor signalling, splicing and transcription. 12 Interestingly, NOVA2 knockdown (KD) by specific siRNAs impair β-cell survival but not insulin secretion, 14 suggesting that the 2 paralogs have different targets in β-cells, as suggested for other tissues. 72 The RBFOX proteins are a highly conserved RNA binding family that regulate alternative splicing. 73 Rbfox1 (A2BP1) and Rbfox2
(RBM9) are preferentially expressed in both human islets and brain. 14 In contrast with the NOVA proteins, Rbfox1 or Rbfox2 KD do not (Figure 2A-C) . These findings suggest a mechanism by which relatively short periods of high glucose exposure potentiate subsequent glucose-induced insulin release and indicate that Rbfox proteins may adapt the insulin secretory capacity to β-cells depending on the physiological demands.
"
Rbfox proteins increases insulin secretion by modulating the splicing of voltage-gated calcium channels and the actin remodelling protein gelsolin (GSN).
Elavl4 is a master regulator of neurogenesis, modulating neuronal survival, function and plasticity. 75 In β-cells, Elavl4 has been previously shown to regulate insulin translation, autophagy and lipid synthesis. 76 Interestingly, Elavl4 inhibition increases basal apoptosis of insulinproducing cells but decreases cell death following exposure to proinflammatory cytokines. 14 This suggests that Elavl4 coordinates different transcripts and pathways depending on the functional state of the β-cells.
| ALTERNATIVE SPLICING, AUTOIMMUNITY AND THE TRIGGERING OF T1D
T1D is chronic autoimmune disease where pancreatic β-cells are targeted and destroyed by infiltrating immune cells and their mediators, such as cytokines and toxic free radicals and by cell-to-cell contacts via FAS-FASL, among others. 77 The mechanisms by which autoimmunity is triggered and progress to disease remain to be clarified, but T1D probably results from the interaction between predisposing genes and environmental factors (eg, viral infections, dietary components, etc.) that lead to the breaking of tolerance to β-cell antigens. [78] [79] [80] This cascade of events is regulated by >50 candidate genes that act on both the immune system and pancreatic β-cells. 10, 79, 80 Genetic alterations (eg, mutations, SNPs) in cis-regulatory elements and trans-acting factors regulating alternative splicing elements can modulate both the susceptibility to autoimmune diseases and disease severity. 81 Associations have been reported between autoimmune disease risk and genetic variants that affect splicing of specific mRNAs, including for instance the interleukin-7 receptor (IL7R) in multiple sclerosis (MS), 82 protein tyrosine phosphatase nonreceptor type 2 (PTPN2) in Crohn's disease, 83 C-type lectin domain family 2 member D (CLEC2D) in T1D 81 and interferon regulatory factor 5 (IRF5) in rheumatoid arthritis. 84 Alternative splicing might also contribute to autoimmunity by affecting the generation and presentation of antigens and lymphocyte homeostasis. 85 Through high depth RNA sequencing of human islets, we found that the pro-inflammatory cytokines IL-1β + IFN-γ-that probably contribute to β-cell death in T1D-change the expression of >30 splicing-regulating RBP. This leads to changes in the β-cell alternative splicing repertoire, affecting the splicing of >3000 genes involved in β-cell function and survival 10, 15 -the gene ontology terms enriched for the genes displaying alternative splicing changes following cytokine exposure are shown in Figure 3 . Interestingly, the "alternative splicing signature" produced by pro-inflammatory cytokines is different from the one produced by the free fatty acid palmitate, a metabolic stressor that may contribute to T2D. 9 These observations suggest that exposure to pro-inflammatory cytokines favour β-cell expression of pro-apoptotic splice variants and potentially lead to the formation of β-cell neoantigens 10 The SRp55 splicing regulator belongs to the SR family of proteins. As discussed above, SR proteins are essential components of the splicing machinery. 88 The role of SR proteins in autoimmune diseases remains poorly explored, but low levels of SRSF1 may contribute to the development of systemic lupus erythematosus, 89 while SRp55 regulates the skipping of CD45 exon 4 during T cell activation, and alterations in CD45 isoform expression levels are associated with autoimmune and infectious diseases. 90 Aberrant expression of SR proteins is present in multiple types of cancer, including leukaemia, kidney, breast, colon, pancreas and lung cancers, among others. 91 SRp55 has been implicated in the development of skin and colorectal cancer. 92, 93 SRp55 is classified as a proto-oncogene, since its overexpression results in hyperplasia, increased cell proliferation and motility. 92, 93 In β-cells, SRp55 gene expression is under regulation of the T1D and T2D susceptibility gene GLIS3, and its expression is decreased by pro-inflammatory cytokines. 11, 13 RNA sequencing analysis of SRp55-depleted human insulin-producing EndoC-βH1 cells, followed
by confirmation experiments in both EndoC-βH1 cells and human islets, indicate that SRp55 regulates a crucial splicing program in pancreatic β-cells. 
| Splicing modifications of pro-apoptotic proteins
The decrease in functional β-cell mass, mostly resulting from apoptosis, is a determining factor for T1D development. 77 Most of the proteins involved in the apoptotic pathways are subject to regulation by alternative splicing, leading to different isoforms with different or even opposing functions. 94 Thus, apoptosis-related proteins such as ligands and receptors (FAS/FASL), adaptor proteins and regulators (TRAF2/3, Smac/DIABLO), Bcl-2 family proteins (Bcl-x, Bak, Bim, Bax) and caspases (Casp2/9/10) are affected by alternative splicing, leading to modifications in their protein solubility, apoptotic potential and cellular localization. 94 The depletion of SRp55 leads to β-cell apoptosis (see above) via activation of the intrinsic apoptotic pathway, 13 at least in part driven by splicing modifications of the pro-apoptotic proteins Bim, Bax, Bak, Bok and Smac/DIABLO. 13 In both rat and human β-cells, SRp55 regulates alternative splicing of the mRNA encoding the pro-apoptotic protein Bim. 11,13 BIM premRNA is spliced in 3 main isoforms: Bim Extra Large (BimEL), Bim Large (BimL) and Bim Small (BimS). 95 BimS is the most potent inducer of apoptosis. The BimEL and BimL isoforms are maintained in a relatively inactive conformation through binding to the microtubuleassociated dynein motor complex, while BimS is constitutively active due to the absence of this dynein-binding domain encoded by the spliced exon 2. 95 Other molecular mechanisms leading to Bim activation may contribute to β-cell death, such as Bim phosphorylation by JNK, which is regulated in these cells by the T1D candidate gene PTPN2. 96 Bim expression is also regulated by β-cell stress-responsive transcription factors, including members of FOXO and activator protein 1 (AP-1) family. 97, 98 Interestingly, transcriptome analysis of cytokine-modified genes indicates an enrichment for AP-1 target genes. 10 SRp55 also regulates the splicing of the pro-apoptotic protein Bax, and SRp55 depletion by specific siRNAs promotes the expression of a constitutively active isoform named Baxβ. 13 Baxβ results from the retention of intron 5, which modifies the encoded transmembrane domain at the Bax C-terminal end. 99 This converts
Baxβ into a constitutively active protein that spontaneously integrates into the mitochondrial membrane, leading to the release of . C, Schematic representation of Rbfox1/2 splicing regulatory mechanism in response glucose that may contribute to increased insulin release. Results are mean AESEM of 4 independent experiments. *P < .05, **P < .01 and ***P < .001 vs. 0 mM glucose; #P < .05, ##P < .01 and ###P < .001, &P < .05, &&P < .01 and &&&P < .001 as indicated by bars. ANOVA followed by Bonferroni post-hoc test SRp55 inhibition modifies the splicing of genes from different layers of the JNK signalling cascade in human β-cells. 13 In particular, increased exon skipping in MAP3K7 and the activator JNK1
increases the pathway activity and contributes to β-cell apoptosis. 13 The MAP3K7 protein structure includes an N-terminal kinase domain, a poorly characterized linker region, and a C-terminal coiled-coil domain. 102 The binding of 2 co-activators-TAB1 and TAB2-are probably required for MAP3K7 autophosphorylation and activation of the downstream kinase cascade, 102 and it remains to be determined how alternative splicing modulates these processes.
| SPLICING MODULATION-A NOVEL APPROACH TO PREVENT β-CELL LOSS IN T1D?
Deciphering the role of alternative splicing in T1D may uncover a new line of therapeutic approaches based on splicing modulatory molecules 103 that can be targeted to β-cells by using cell surface biomarkers. 86, 87 RNA splicing is an interesting point for intervention since it is an early step in gene expression and represents a non-permanent 
| Antisense oligonucleotides (AONs)
AONs are short oligonucleotide sequences of around 20 bp in length, designed as the reverse complement of a specific sequence in the pre mRNA. 103 Their design relies on the principle that AONs-specific hybridization to the target region on the pre mRNA blocks the access of splicing machinery components, redirecting the splicing to an The sequence specificity of AONs allow them to bind precisely to their target, while fidelity allows targeting of distinct RNA isoforms. 103 The AONs need to be chemically modified to improve stability and internalization by the target cells. 103 The AONs approach has evolved from proof of concept in in vitro studies and animal tests into clinical trials for Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). 105, 108 AONs can also be designed to target cisregulatory regions and promote specific alternative splicing shifts. 109 Targeting the RNA regulatory elements has major advantages over targeting the RBP directly: while direct inhibition of an RBP will affect a broad range of downstream biological mechanisms, the AON-if adequately designed-will only affect the target mRNA.
This approach may have a potential use in T1D. Thus, CTLA-4 splicing modulation reduces the incidence of insulitis and diabetes in NOD mice by interfering with T cell activation and proliferation, 110 while microparticles carrying AONs targeting CD40, CD80 and CD86 prevent or reverse diabetes in the same mouse model. 111 In human β-cells, several isoforms that contribute to β-cell death are potential targets for AON splicing modulation, including BimS, BAXβ and JNK (our own unpublished data).
| Small molecules
Small molecules that interfere with splicing are often identified by high-throughput in vitro screens. They either directly modify the activity/localization of spliceosomal core components and RBPs or affect them indirectly, via targeting RNA sequences that prevent their binding to pre-mRNAs. 112 Potential limitations of these small molecules are lack of specificity and lack of detailed information regarding their biologic mechanism of action, which might lead to off target effects. 103 Some of these small molecules are already used in clinical practice. One example is pentamidine, an antimicrobial that partially rescues splicing defects observed in myotonic dystrophy. 113 Another molecule, dantrolene, enhances by >10-fold AON-mediated exon 51 skipping in DMD myotubes. 114 Potential splicing modifier molecules that increase SMN protein expression have also been identified. 115 Given their effect on the basal splicing machinery, it is curious that these molecules have a certain degree of specificity. For example the spliceostatin A molecule, despite targeting a component of snRNP, was shown by microarray analysis to affect preferentially alternative splicing patterns of genes involved in cell cycle. 116 
| CONCLUSION AND FUTURE PERSPECTIVES
Recent evidence suggests that master splicing factors and their downstream alternative exon networks have an important role in maintaining β-cell identity and phenotype, as well as in regulating their adaptation to extracellular cues such as immune-induced stress. These findings highlight the role of "neuron-specific" splicing factors in β-cells 14 and suggest that SRp55, a splicing regulator downstream of the diabetes candidate gene GLIS3, is a key splicing factor in human pancreatic β-cells. 13 This hints of a potential crosstalk between candidate genes for diabetes and alternative splicing regulation that must be further explored.
The regulation and role of alternative splicing in pancreatic β-cells remains "terra incognita." The data discussed above describes the initial attempts to chart this new territory. Many fundamental questions, however, remain:
1. Which splicing events will actually lead to relevant biological out- AON) ; B, Predicted binding between BIM.AON (blue line) and BIM pre-mRNA target region. The predicted structures were obtained using RNA structure software 4. Can the identification of β-cell-specific splice variants generate useful biomarkers for β-cell imaging or to monitor, via circulating biomarkers, the progressive β-cell loss in diabetes?
5. Is it possible to modulate β-cell alternative splicing in vivo, and thus prevent β-cell death?
6. If yes, and considering that some of these spliced pro-apoptotic proteins (such as BimS) are expressed in other tissues and may act as anti-oncogenic proteins, how to obtain specific delivery of alternative splicing modulators to β-cells?
In conclusion, alternative splicing is an unexplored layer of regulation of β-cell function and survival. A better characterization of its role in β-cells will hopefully let the passage of more than "half of a person (or truth) each time" and lead to a comprehensive understanding of β-cells at its real level of complexity.
